News

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...
An urgent warning has been issued by one Aussie health authority after medical staff reportedly gave the wrong RSV ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...
A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...
A reshaped agenda for the Centers for Disease Control and Prevention's (CDC) vaccine advisory committee meeting on June 25–26 signals a departure from the initial vaccine slate. New appointees named ...
Sanofi (Euronext: SAN) has signed a strategic agreement with health authorities in Abu Dhabi to accelerate vaccine development and manufacturing in the United Arab Emirates. The deal was announced at ...
However, upon its commercial launch, Enflonsia is likely to face stiff competition from AstraZeneca AZN / Sanofi ’s SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023 ...
Enflonsia joins a short list of new tools to prevent RSV in infants. Another RSV antibody called Beyfortus, made by Sanofi and AstraZeneca, was approved in 2023. But there were supply shortages during ...
BofA Securities lowered its price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR8.40 from EUR8.48 on Tuesday, while maintaining a Buy rating on the French pharmaceutical company’s stock. With a ...